927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients.

Authors :: Forster, M.
Felip, E.
Doger, B.
Lopez Pousa, A.
Carcereny, E.
Bajaj, P.
Church, M.
Peguero, J.
Roxburgh, P.
Triebel, F.
Source :: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS667-S667. 1p.
Publication Year :: 2020

Subjects :: *HEAD & neck cancer
*CANCER patients
*PROGRAMMED death-ligand 1
*PEMBROLIZUMAB
*METASTASIS

Full Text Access

Tools